Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abeona Therapeutics Inc. - Common Stock (NQ:ABEO)

5.070 +0.030 (+0.60%)
Streaming Delayed Price Updated: 12:28 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Abeona Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics Announces New Employee Inducement Grants
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics Announces Update on AAV Ophthalmology Program
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Three Small-Cap Biotech Stocks to Consider Now
This article looks at three small-cap biotech companies with stock prices that are making significant moves and have a bright outlook for 2023 
Via MarketBeat
News headline image
Abeona Therapeutics Reports Third Quarter 2022 Financial Results
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics Announces $35 Million Private Placement Financing
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Topline VIITAL™ study results expected within the next month 
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics Inc. (NASDAQ:ABEO) Investor Alert: Investigation over Potential Wrongdoing ↗
San Diego, CA -- (SBWIRE) -- 04/08/2021 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Abeona Therapeutics Inc. 
Via SBWire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.